Back to results
US 2006/0149062 A1Published application
Sulfanyl substituted phenyl methanones
OwnerSynese Jolidon, Robert Narquizian +2inventors
InventorsSynese Jolidon, Robert Narquizian, Roger Norcross, Emmanuel Pinard
Life of this patent
Estimating the term…
Abstract
The present invention relates to compounds of formula I wherein R1, R2, R3, X, X1, and n are as defined in the specification and pharmaceutically acceptable acid addition salts thereof. These compounds are good inhibitors of the glycine transporter 1 (GlyT-1) for the treatment CNS disorders, such as schizophrenia, cognitive impairment, and Alzheimer's disease.
Claims25
A compound of formula I
- wherein
- R1 is lower alkyl or lower alkyl substituted by halogen;
- R2 is —S(O)2-lower alkyl, —S(O)2NH-lower alkyl, NO2 or CN;
- R3 is halogen, CN, lower alkyl, lower alkyl substituted by halogen, NO2, —C(O)-lower alkyl or S(O)2-lower alkyl;
- X and X1 are each independently CR4 or N;
- R4 is hydrogen or halogen;
- and
- n is 0, 1 or 2;
- or a pharmaceutically acceptable acid addition salt thereof.
6 more elements
A pharmaceutical composition comprising a compound of formula
- wherein
- R1 is lower alkyl or lower alkyl substituted by halogen;
- R2 is —S(O)2-lower alkyl, —S(O)2NH-lower alkyl, NO2 or CN;
- R3 is halogen, CN, lower alkyl, lower alkyl substituted by halogen, NO2, —C(O)-lower alkyl or S(O)2-lower alkyl;
- X and X1 are each independently CR4 or N;
- R4 is hydrogen or halogen;
- and
- n is 0, 1 or 2;
- or a pharmaceutically acceptable acid addition salt thereof and a pharmaceutically acceptable carrier.
6 more elements
Dependencies are inferred from the claim text.